Clinical Trials Directory

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections

The purpose of the study is to compare the safety and efficacy of Isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

Stanford is now accepting new patients for this trial. Please contact Physician Referrals at 650-723-0822 for more information.



  • drug : Isavuconazole
  • drug : Voriconazole
  • drug : Caspofungin

Phase: Phase 3


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients with candidemia or with an invasive Candida infection - Presence of fever, hypothermia or other appropriate local sign of infection - Female patients must be non-lactating and at no risk of pregnancy

External Links

Explore related trials

Contact information

Primary Contact:

Physician Referrals 650-723-0822

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: